Jan D. Hirsch, BS Pharm, PhD Research Interests Pharmacoeconomics & Outcomes Research “Value” of...
-
Upload
daisy-adams -
Category
Documents
-
view
220 -
download
0
Transcript of Jan D. Hirsch, BS Pharm, PhD Research Interests Pharmacoeconomics & Outcomes Research “Value” of...
Jan D. Hirsch, BS Pharm, PhDResearch Interests
Pharmacoeconomics & Outcomes Research
“Value” of Pharmacist Services & Pharmaceuticals - Economic, clinical and humanistic outcomes - Diabetes, hypertension, gout, mental health, HIV/AIDS, gout… - Novel pharmacy practice models
Health Related Quality of Life (HRQOL) - Develop and assess instruments for clinical trials and
practice - Gout Impact Scale (GIS) in multinational clinical trials for
new therapies - Student Quality of Life, Stress, & Coping Skills
Core Expertise
Assessing Patient Reported Outcomes (PROs)- Patient/subject perceptions, attitudes, knowledge, intentions, symptoms- Health Related Quality of Life (HRQOL)
Instrument development and validationAssessment across patient groups, countries, cultures
Assessing outcomes (ECHO) in patient populations - identify patients likely to benefit most from new intervention (best value) - change in outcomes due to new vs. usual care interventions
Pre-market “value” of new pharmaceuticals- Economic, clinical and humanistic value propositions
- Given current and likely future market conditions- Evidence required for reimbursement by payers all countries- Pharmacoeconomic research strategy and plan to collect and
disseminate needed data
Proposed Collaborations with SSPPS Faculty
Assessing Patient Reported Outcomes (PROs)- Patient/subject perceptions, attitudes, knowledge, intentions, symptoms- Health Related Quality of Life (HRQOL)
Instrument development and validationAssessment across patient groups, countries, cultures
Assessing outcomes (ECHO) in patient populations - identify patients likely to benefit most from new intervention (best value) - change in outcomes due to new vs. usual care interventions
Pre-market “value” of new pharmaceuticals- Economic, clinical and humanistic value propositions
- Given current and likely future market conditions- Evidence required for reimbursement by payers all countries- Pharmacoeconomic research strategy and plan to collect and
disseminate needed data
Clin
ical
Fac
ulty
Pha
rm S
cien
ces